🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

PSMA-Guided Surgery and Tissue-Resident T-Cell Profiling in Node-Positive Prostate Cancer

RecruitingNAAges 18 Years - 85 YearsMaleNiguarda Hospital
NCT07879820 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

TACTIC-P is a single-center, prospective, single-arm study in 12 men with biopsy-proven prostate cancer and pelvic lymph-node uptake on preoperative PSMA PET, without bone or visceral metastases, who are scheduled for robot-assisted radical prostatectomy and extended pelvic lymph-node dissection. On the day of surgery, participants receive intravenous gallium-68 PSMA-11 followed by PET/CT and PSMA-radioguided surgery using a drop-in gamma probe. Resected prostate tumor, metastatic lymph-node tissue, and matched blood samples are used for high-dimensional immune profiling. The main goal is to determine whether functional pathogen-specific bystander tissue-resident T cells can be identified and quantitatively characterized in the primary tumor and/or metastatic lymph nodes. The study also evaluates immune features relevant to future personalized immunotherapy, the ability of PSMA-radioguid

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male participants. * Age 18 to 85 years. * Biopsy-proven prostate cancer with positive lymph nodes on staging PSMA PET (miN+). * Planned robot-assisted radical prostatectomy with extended pelvic lymph-node dissection. * Able to understand and willing to sign written informed consent. Exclusion Criteria: * Neoadjuvant hormonal therapy before surgery. * Inability to complete imaging examinations according to the protocol. * Bone or visceral metastatic disease (M1b-c) on preoperative imaging. * Life expectancy \<12 months. * Previous chemotherapy. * Previous brachytherapy or external-beam radiotherapy. * Congestive heart failure. * Any other significant disease/disorder that, in the investigator's opinion, may increase risk, influence study results, or impair participation. * History of allergic disease/reactions likely to be exacerbated by study IMPs or radiotracer components (68Ga-PSMA). * Experimental drug within 30 days before radiotracer administration or within 5 half-lives of that experimental drug.
💊

What it tests

  • PSMA-Radioguided Robot-Assisted Radical Prostatectomy With Extended Pelvic Lymph-Node Dissection
📍

Where

1 site
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy